Therapeutic Strategies for Metastatic Melanomas

Dear Colleagues,

Over the last few years, the prognosis of metastatic melanoma patients has improved significantly due to new treatment options, such as checkpoint inhibition and targeted therapy. However, most efficacy data were obtained from randomized phase III trials with strict inclusion and exclusion criteria. As a consequence, there is a great need for data from clinical practice (real world data), for example, from registries that also address patients with, e.g., comorbidities or noncutaneous melanomas that were excluded in the clinical trials.
This Special Issue will highlight the current status of metastatic melanoma therapy and potential future prospects.
Manuscripts are welcome that report on original data or updated, comprehensive literature reviews in the field of melanoma therapy.
The following topics are of particular interest:

• Long term survival of melanoma patients under checkpoint inhibition and/or targeted therapy;
• Real world data on adjuvant therapy of metastatic melanoma patients;
• New possibilities for therapy monitoring of melanoma patients, such as liquid biopsies;
• Real world data/therapy options for difficult-to-treat melanoma subtypes such as mucosal melanoma, acral melanoma, and uveal melanoma;
• - Therapy options for advanced liver metastasis, such as chemosaturation, SIRT, stereotaxy, surgery.

Other topics may also be of interest and will be considered.

Dr. Andrea Forschner
Dr. Elisabeth Livingstone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.